Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Cash from Financing Activities: 2017-2025

Historic Cash from Financing Activities for Autolus Therapeutics (AUTL) over the last 2 years, with Sep 2025 value amounting to -$1.8 million.

  • Autolus Therapeutics' Cash from Financing Activities fell 1058.92% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.6 million, marking a year-over-year decrease of 95.06%. This contributed to the annual value of $589.6 million for FY2024, which is 66867.16% up from last year.
  • According to the latest figures from Q3 2025, Autolus Therapeutics' Cash from Financing Activities is -$1.8 million, which was down 130.99% from -$768,000 recorded in Q2 2025.
  • Autolus Therapeutics' Cash from Financing Activities' 5-year high stood at $561.4 million during Q1 2024, with a 5-year trough of -$2.1 million in Q2 2024.
  • In the last 3 years, Autolus Therapeutics' Cash from Financing Activities had a median value of -$455,000 in 2023 and averaged $73.3 million.
  • Per our database at Business Quant, Autolus Therapeutics' Cash from Financing Activities slumped by 69,000.00% in 2023 and then soared by 81,350.51% in 2024.
  • Autolus Therapeutics' Cash from Financing Activities (Quarterly) stood at $147.4 million in 2021, then plummeted by 100.00% to -$1,000 in 2022, then tumbled by 69,000.00% to -$219,000 in 2023, then plummeted by 849.32% to $30.0 million in 2024, then plummeted by 1,058.92% to -$1.8 million in 2025.
  • Its Cash from Financing Activities stands at -$1.8 million for Q3 2025, versus -$768,000 for Q2 2025 and $30.0 million for Q4 2024.